Newsletter | November 18, 2026

11.18.26 -- OPCU: Strengthening Cell And Gene Therapy Programs With Robust Analytics

 

 

Cell and gene therapies bring a level of complexity that puts analytical capabilities at the center of development. Characterizing living and highly variable products, developing potency assays, establishing release testing, and maintaining comparability through process changes all shape how quickly and confidently a program can advance.

 

Building an analytical strategy alongside the manufacturing process can help sponsors reduce risk, support regulatory expectations, and prepare for the demands of later-stage and commercial supply. In this edition of the Outsourced Pharma Capabilities Update (OPCU), hear from CDMOs and service providers addressing key considerations across cell and gene therapy development and analytical services, from process development and characterization to method validation and quality control. Watch the presentations below for perspectives on aligning analytics and manufacturing to support your program’s progress.

 

Recent Sessions Available On-Demand                                
 AI Drug Manufacturing & Viral Vectors – October 2026                            
 mRNA & Packaging, Labeling & Logistics – October 2026                            
 Fill/Finish – October 2026                            
 ADC – October 2026                        

 

Upcoming OPCU Topics & Times              
 Enabling ADC Success | 12/1/2026, PM Session                              
 Mastering Aseptic Fill-Finish | 12/1/2026, PM Session                          

 

Access more on-demand OPCU recordings and upcoming sessions here.

ANALYTICS/LAB SERVICES

Solvias

This presentation explores expertise across a broad range of advanced modalities, including viral vectors, mRNA and lipid nanoparticles, gene-editing tools, and cell-based therapies.

Request Information

Solvias

Alcami

Learn how rigorous microbial challenge programs are designed and executed, with practical lessons for overcoming challenges and demonstrating microbiological safety.

Request Information

Alcami

KBI Biopharma

Anticipate analytical challenges early to prevent commercialization delays. Integrated characterization and quality strategies streamline tech transfer, reduce risk, and support regulatory success.

Request Information

KBI Biopharma

CELL AND GENE

ProBio

In vivo CAR-T therapies could expand access and lower costs by eliminating ex vivo manufacturing. Robust CMC strategies, vector design, and analytics are key to accelerating clinical translation.

Request Information

ProBio

Andelyn Biosciences

Achieving commercial readiness for AAV gene therapies starts early. Prioritizing assay lock, process qualification, and supply chain security reduces risk and supports reliable patient supply.

Request Information

Andelyn Biosciences